Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ANIP 
ANI Pharmaceuticals Inc (ANIP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ANIP (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $99
1 Year Target Price $99
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 39.4% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.12B USD | Price to earnings Ratio - | 1Y Target Price 99 |
Price to earnings Ratio - | 1Y Target Price 99 | ||
Volume (30-day avg) 6 | Beta 0.63 | 52 Weeks Range 52.50 - 99.50 | Updated Date 09/16/2025 |
52 Weeks Range 52.50 - 99.50 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -1.37% | Operating Margin (TTM) 7.18% |
Management Effectiveness
Return on Assets (TTM) 1.09% | Return on Equity (TTM) -2.17% |
Valuation
Trailing PE - | Forward PE 12.42 | Enterprise Value 2565964561 | Price to Sales(TTM) 2.83 |
Enterprise Value 2565964561 | Price to Sales(TTM) 2.83 | ||
Enterprise Value to Revenue 3.43 | Enterprise Value to EBITDA 28.82 | Shares Outstanding 21688800 | Shares Floating 16998770 |
Shares Outstanding 21688800 | Shares Floating 16998770 | ||
Percent Insiders 10.42 | Percent Institutions 97.91 |
Upturn AI SWOT
ANI Pharmaceuticals Inc
Company Overview
History and Background
ANI Pharmaceuticals, Inc. was founded in 2003. It is a specialty pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.
Core Business Areas
- Generic Pharmaceuticals: Focuses on manufacturing and marketing generic prescription drugs, which are off-patent versions of branded drugs. This segment constitutes a significant portion of ANI's revenue.
- Branded Pharmaceuticals: Involves developing and marketing branded prescription drugs, which are often niche products. This segment provides higher profit margins but also involves greater risks.
- Contract Manufacturing: Provides contract manufacturing services for other pharmaceutical companies, utilizing its manufacturing capabilities and expertise.
Leadership and Structure
Nikhil Lalwani serves as the President and CEO. The company has a typical corporate structure with various departments including R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- EEMTu00ae: A branded combination drug product for the treatment of hypothyroidism. Market share data is not publicly available in a precise form. Competitors include other thyroid hormone replacement therapies and manufacturers of similar combination drugs. Revenue is not broken out for individual products.
- Generic Adrenocorticotropic Hormone (ACTH): A generic version of H.P. Acthar Gel. Market share varies and is not publicly available in a precise form. Competitors include Mallinckrodt (Acthar Gel) and other potential generic entrants. Revenue not broken out for individual products.
- Cortrophin Gel: A purified porcine ACTH indicated for various conditions.Market share varies and is not publicly available in a precise form. Competitors include Mallinckrodt (Acthar Gel) and other potential generic entrants. Revenue not broken out for individual products.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Generic drug manufacturers face pricing pressure, while branded drug companies face patent expirations.
Positioning
ANI Pharmaceuticals is positioned as a specialty pharmaceutical company focusing on both generic and branded drugs. Its competitive advantage lies in its manufacturing capabilities and ability to acquire and develop niche products.
Total Addressable Market (TAM)
The pharmaceutical market is valued at over $1 trillion globally. ANI is positioned within the generic and specialty branded drug segments, with its TAM dependent on the specific therapeutic areas and product portfolios it serves.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Strong manufacturing capabilities
- Experienced management team
- Focus on niche markets
Weaknesses
- High debt levels
- Dependence on key products
- Vulnerability to pricing pressure in the generic market
- Limited R&D pipeline compared to larger companies
Opportunities
- Acquisitions of complementary products or companies
- Expansion into new markets
- Development of new generic drugs
- Partnerships with other pharmaceutical companies
Threats
- Increased competition from generic drug manufacturers
- Regulatory changes
- Patent expirations
- Pricing pressure from payers
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- ENDP
Competitive Landscape
ANI Pharmaceuticals faces intense competition from larger generic drug manufacturers. Its competitive advantage lies in its focus on niche markets and its manufacturing capabilities.
Major Acquisitions
Alimera Sciences, Inc. U.S. product portfolio
- Year: 2024
- Acquisition Price (USD millions): 82.5
- Strategic Rationale: Expanded product portfolio and strengthened position in the ophthalmic market.
Growth Trajectory and Initiatives
Historical Growth: ANI has grown through acquisitions and organic growth of its product portfolio.
Future Projections: Future growth is expected to come from new product launches and strategic acquisitions. Analyst estimates vary.
Recent Initiatives: Recent initiatives include acquisitions of new products and efforts to expand its manufacturing capabilities.
Summary
ANI Pharmaceuticals is a specialty pharmaceutical company with a diverse portfolio of branded and generic drugs. Its strengths lie in its manufacturing capabilities and focus on niche markets, while its weaknesses include high debt and dependence on key products. The company faces threats from increased competition and regulatory changes but has opportunities to expand through acquisitions and new product development. The company's long-term success depends on its ability to manage its debt and successfully launch new products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Financial news sources
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ANI Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Baudette, MN, United States | ||
IPO Launch date 2000-05-05 | President, CEO & Director Mr. Nikhil Lalwani | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 897 | |
Full time employees 897 | |||
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.